Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 3/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 3/20 | 0.47 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16984895 | 0.97 | MME (0.48) | MMEANPEPPOLBTACR1ACE | |
| SCHEMBL16984900 | 0.93 | MME (0.42) | MMEANPEPPOLBTACR1ACE | |
| SCHEMBL16984883 | 0.92 | CAPN1 (0.53) | CTSLCTSK | |
| SCHEMBL16984799 | 0.91 | CTSC (0.47) | MMEANPEPPOLBTACR1ACE | |
| SCHEMBL16984903 | 0.91 | CTSL (0.42) | MMEANPEPPOLBCTSLCTSB | |
| SCHEMBL16984886 | 0.88 | CTSC (0.45) | MMEANPEPPOLBTACR1ACE | |
| SCHEMBL16984915 | 0.88 | CTSL (0.43) | MMEANPEPACECTSLCTSB | |
| SCHEMBL16984885 | 0.88 | MME (0.47) | MMEANPEPPOLBTACR1CTSL | |
| SCHEMBL16970552 | 0.88 | MME (0.55) | MMEACE | |
| SCHEMBL16984876 | 0.87 | CTSK (0.51) | CTSLCTSBCTSSCTSKMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160347792-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | TRILLIUM THERAPEUTICS INC. (CA) | 2016-12-01 | — | — | US | disclosed |
| US-9441012-B2 | Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors | TRILLIUM THERAPEUTICS INC. (CA) | 2016-09-13 | — | — | US | disclosed |
| US-20150218212-A1 | FLUORINATED EPOXYKETONE-BASED TETRAPEPTIDE COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | FLUORINOV PHARMA INC. (CA) | 2015-08-06 | — | — | US | disclosed |
| US-20150203534-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | FLUORINOV PHARMA INC. (CA) | 2015-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347792-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | PSMB5, PSMB1, PSMB7 | MME 494/4885ANPEP 1458/4885POLB 1029/4885 |
| US-20150218212-A1 | FLUORINATED EPOXYKETONE-BASED TETRAPEPTIDE COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | PSMA1, PSMB1, PSMB11 | MME 192/4885ANPEP 119/4885POLB 1372/4885 |
| US-20150203534-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | PSMB5, PSMB1, PSMB7 | MME 553/4885ANPEP 1532/4885POLB 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.